Premature Ovarian Insufficiency Clinical Trial
Official title:
Women's Experience of Premature Ovarian Insufficiency (POI) Diagnosis: Update on Actual Practices and Patient's Follow up
Premature ovarian insufficiency (POI) affects 2,8 to 3,5% of women before the age of 40. Previous foreign studies revealed that only half of POI disclosures occurred during a medical consultation and that the diagnosis was often discussed in less than 5 minutes. As a result, most of patients felt a lack of information, and consequently sought data on the internet. None of these studies were conducted in France. The aim of this study is to analyze current practices related to POI diagnosis and to assess women's satisfaction
POI is defined by the association of 1 clinical and 1 biological criterion: amenorrhea or spaniomenorrhea of > 4 months with onset before 40 year of age, and elevated follicle-stimulating hormone (FSH) > 25 IU/L on 2 assays at > 4 weeks' interval, associated with low estradiol level. This condition affects approximately 2% of young women. POI can first lead to infertility and various symptoms caused by a lack of estrogens. Thus, patients may experience vaso-motor flushes, genitourinary syndrome, sleep disturbance, humor disorder, decrease libido and dyspareunia. After several years, POI can lead to osteoporosis, increased cardiovascular risk, and dementia. The administration of hormone replacement therapy (HRT) can help prevent these complications. Otherwise, POI may result in psychological repercussions such as anxiety, anger, loss of self-esteem, even depression. Few studies analyzed POI diagnosis and the way it was perceived by patients. Alzubaidi et al. and subsequently Groff et al. reported that only half of POI notifications occurred during a medical consultation. Moreover, 35% of the consultations lasted less than 5 minutes. Thereby, Singer et al. founds that 68% of women felt inadequately informed. The majority of patients sought additional information on the internet. No recent study focused on the disclosure of POI diagnosis, and none of the existing studies were conducted in France. The purpose of this study is to analyze the circumstances surrounding POI diagnosis and to evaluate women's experience. In other ways, in 2016, Bachelot et al. emphasized that after more than 5 years after POI diagnosis, only 61,7% of women were undergoing HRT whereas only 6% had no regular follow-up. Moreover, among the treated patients, 42,6% had already stopped HRT for more than 1 year without any medical recommendation. Therefore, this study aims to examine the association between women satisfaction regarding POI disclosure and their compliance to HRT and medical follow-up ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06072794 -
A Proof of Concept Study to Evaluate Exosomes From Human Mesenchymal Stem Cells in Women With Premature Ovarian Insufficiency (POI)
|
Phase 1 | |
Recruiting |
NCT06096766 -
the Correlation Between Ovarian Function and Serum Biomarkers
|
||
Completed |
NCT04641624 -
sFlt- 1, PIGF, and Niacin Levels in Women With Premature Ovarian Insufficiency
|
||
Recruiting |
NCT05308342 -
Clinical Study of Human Umbilical Cord Mesenchymal Stem Cells in the Treatment of Premature Ovarian Insufficiency
|
N/A | |
Not yet recruiting |
NCT06067529 -
A Multicenter Observational Study on the Development and Health Effects of Premature Ovarian Insufficiency
|
||
Recruiting |
NCT05665010 -
Precise Stratification of Genetic Risk of Ovarian Function Impairment
|
||
Not yet recruiting |
NCT05385848 -
Autologous Platelet-rich Plasma (PRP) Infusion to Improve Outcomes in Women With Ovarian Insufficiency: a Pilot Study
|
N/A | |
Completed |
NCT04475744 -
4-step ASCOT in POI Women to Promote Follicular Rescue
|
Phase 3 | |
Recruiting |
NCT05279560 -
Ovarian PRP (Platelet Rich Plasma) Injection for Follicular Activation
|
N/A | |
Recruiting |
NCT06302543 -
Treatment of Premature Ovarian Insufficiency Using Bone Marrow Cells
|
N/A | |
Recruiting |
NCT06145061 -
Evaluation on Biological Characteristics of Acupoints in Premature Ovarian Insufficiency
|
||
Recruiting |
NCT05858307 -
Clinical Application of Serum Anti-Müllerian Hormone (AMH) Measurements
|
||
Recruiting |
NCT06102655 -
Effect and Mechanism of Jiajian Guishen Formulation on Premature Ovarian Insufficiency Based on Metabolomics
|
Early Phase 1 | |
Recruiting |
NCT05485610 -
Effect of NMN (Nicotinamide Mononucleotide) on Diminished Ovarian Reserve (Including Premature Ovarian Insufficiency)
|
N/A | |
Recruiting |
NCT05586737 -
Immunomodulatory Therapy in Women With Autoimmune Premature Ovarian Insufficiency
|
Phase 2 | |
Recruiting |
NCT04167033 -
Ventricular Repolarization in Patients With Premature Ovarian Insufficiency (QT-IOP)
|
N/A | |
Not yet recruiting |
NCT06339489 -
The Bone Metabolism Characteristics of Premature Ovarian Insufficiency
|